Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2020. Investors. Notes As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). This press release and further information about Alexion can be found at: www.alexion.com. The negative impact of foreign currency on total revenues year-over-year was 2 percent, or $25.5 million, inclusive of hedging activities. Investor Relations +1(617)-429-6891. Sustainability Access to healthcare 2018 Annual Report. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies. As a result, we recognized a gain on the sale during the three and nine months ended September 30, 2020. We continue to take steps to proactively respond to the evolving COVID-19 pandemic and to plan for related uncertainties. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. ... Chris Stevo-- Head of Investor Relations. During the three and nine months ended September 30, 2020, we recorded $14.3 million of restructuring expenses relating to restructuring activities initiated during the third quarter 2020 primarily within our commercial organization. 2019 Annual Report. AstraZeneca Investor Relations: US general enquiries +1 301 398 3251: Alexion Investor Relations: investorrelations@alexion.com: AstraZeneca (AZN) & Alexion (ALXN) Merger. We use cookies to give you the best online experience. 2018 Annual Report. By using our website, you agree to our use of cookies in accordance with our, 39th Annual J.P. Morgan Healthcare Conference, 3rd Annual Evercore ISI HealthCONx Conference, Alexion Pharmaceuticals, Inc. Third Quarter 2020 Results, Morgan Stanley’s 18th Annual Global Healthcare Conference, Alexion Pharmaceuticals, Inc. Second Quarter 2020 Results, 2020 Bank of America Virtual Napa Biotech Conference, 41st Annual Global Goldman Sachs Healthcare Conference, Alexion Pharmaceuticals, Inc. First Quarter 2020 Results, Alexion To Acquire Portola Pharmaceuticals. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Changes in the fair value of contingent consideration expense for the three and nine months ended September 30, 2020 reflect changes in the expected timing and probability of achieving contingent milestone payments, and the interest component of contingent consideration related to the passage of time. The 2020 GAAP and non-GAAP tax rates do not benefit from one-time events that benefited the tax rates in 2019. We make some of the world’s best-known brands – all are on a journey to reducing their environmental footprint and increasing their positive social impact. For details on how to contact the Investor Relations Team, please click here. Contacting Vertex's Transfer Agent. © 2021 Alexion Pharmaceuticals, Inc. https://www.businesswire.com/news/home/20201029005154/en/, Established ULTOMIRIS as new standard of care in PNH ahead of set goal, with more than 70% patient conversion from SOLIRIS, Initiated Phase 3 program for CAEL-101 in AL amyloidosis in collaboration with Caelum Biosciences, Raised full year guidance, driven by increased revenue guidance of. Press Releases Media centre Articles Image library COVID-19 visual resources Broadcast videos Archive Media contacts Sustainability. By using our website, you agree to our use of cookies in accordance with our, Alexion Reports Third Quarter 2020 Results. Non-GAAP income tax expense for the nine months ended September 30, 2019 also excludes certain one-time tax benefits of $95.7 million and $30.3 million associated with a tax election made with respect to intellectual property of Wilson and a release of an existing valuation allowance, respectively. BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN). This press release contains forward-looking statements, including statements related to: guidance regarding anticipated financial results for 2020 (and the assumptions related to such guidance); our expectations regarding the affects COVID-19 will have on our business and operations, including clinical trials and product supply; the strength of our business and continued growth; the Company's capital allocation strategy; plans to expand the Company's pipeline; future plans for, and the timing for, the commencement of future clinical trials and the expected timing of the receipt of results of certain clinical trials and studies, including clinical programs for ULTOMIRIS, a higher concentration formulation of ULTOMIRIS, a subcutaneous administration of ULTOMIRIS, SOLIRIS, ALXN1840, CAEL-101, ALXN2060, ALXN2040, ALXN2050, ALXN1720, ALXN1830, ANDEXXA and CERDULATINIB; potential benefits of current products and products under development and in clinical trials; plans for development programs with third parties; and Alexion's future clinical, regulatory, and commercial plans for ULTOMIRIS and other products and product candidates. Alexion will host a conference call/audio webcast to discuss the third quarter 2020 results today at 8:00 a.m. Eastern Time. Feb 4, 2021. Alexion Statement on SOLIRIS® (eculizumab) and COVID-19 In early February, in response to the government’s outreach, Alexion reached out to the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) office, the Department of Defense (DoD) and others within government to discuss the potential use of SOLIRIS ® (eculizumab) in patients … Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law. BOSTON--(BUSINESS WIRE)--Oct. 29, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2020. © 2021 Alexion Pharmaceuticals, Inc. The audio webcast can be accessed on the Investor page of Alexion’s website at: http://ir.alexion.com. During the nine months ended September 30, 2020, we recorded $21.6 million in litigation charges in connection with legal proceedings. 2018 Annual Report. Please refer to the attached Reconciliations of GAAP to non-GAAP Financial Results and GAAP to non-GAAP 2020 Financial Guidance for explanations of the amounts adjusted to arrive at non-GAAP net income and non-GAAP earnings per share amounts for the three and nine month periods ended September 30, 2020 and 2019 and projected twelve months ending December 31, 2020. To participate in the call, dial 866-762-3111 (USA) or 210-874-7712 (International), conference ID 6582445 shortly before 8:00 a.m. Eastern Time. 3.3 MB. Chris Stevo-- Head of Investor Relations. "We have continued to build on our momentum from the first half of the year, delivering another strong quarter despite the ongoing challenges and uncertainty surrounding COVID-19. Questions may be directed to the Investor Relations team via e-mail at InvestorRelations@Alexion.com or the contact information below. Stock Information. Find the latest SEC Filings data for Alexion Pharmaceuticals, Inc. Common Stock (ALXN) at Nasdaq.com. In this role, she is responsible for overseeing global financial management, treasury, internal audit, corporate strategy, business development, investor relations, security activities, and business operations, including corporate planning, at Alexion. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for, or superior to, the financial measures prepared and presented in accordance with GAAP, and should be reviewed in conjunction with the relevant GAAP financial measures. Changes in operating assets and liabilities, excluding the effect of acquisitions: Prepaid expenses, right of use operating assets and other assets, Accounts payable, accrued expenses, lease liabilities and other liabilities, Net cash provided by operating activities, Purchases of available-for-sale debt securities, Proceeds from maturity or sale of available-for-sale debt securities, Purchases of mutual funds related to nonqualified deferred compensation plan, Proceeds from sale of mutual funds related to nonqualified deferred compensation plan, Purchases of strategic equity investments and options, Purchases of property, plant and equipment, Payment for acquisition of businesses, net of cash and restricted cash acquired, Net proceeds from issuance of common stock under share-based compensation arrangements, Effect of exchange rate changes on cash and cash equivalents and restricted cash, Net change in cash and cash equivalents and restricted cash, Cash and cash equivalents and restricted cash at beginning of period, Cash and cash equivalents and restricted cash at end of period, View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005154/en/, Media "Our foundation for the future is stronger than ever, and by maintaining our focus on serving patients and delivering for shareholders, I am confident that we will continue to build on our success to date and further advance our mission of delivering life-changing therapies to people with rare diseases and devastating conditions.". Corporate. Alexion’s financial guidance is based on current foreign exchange rates net of hedging activities and does not include the effect of acquisitions, license and other strategic agreements, intangible asset impairments, litigation charges, changes in fair value of contingent consideration, gains or losses related to strategic equity investments or restructuring and related activity outside of the previously announced activities that may occur after the issuance of this press release. Alexion: Media Megan Goulart, 857-338-8634 Senior Director, Corporate Communications Investors Susan Altschuller, Ph.D., 857-338-8788 Vice President, Investor Relations Achillion: Media Susanne Heinzinger, 215-709-3032 Senior VP, Corporate Communications Investors A. Clayton Robertson, 215-709-3078 Manager, Investor Relations Morgan joined Alexion in June 2018 as a member of the Investor Relations team before becoming Chief of Staff to the CEO. In addition to financial information prepared in accordance with GAAP, this press release also contains non-GAAP financial measures that Alexion believes, when considered together with the GAAP information, provide investors and management with supplemental information relating to performance, trends and prospects that promote a more complete understanding of our operating results and financial position during different periods. Alexion contacts. Chris Stevo, 857-338-9309 Company Profile. The non-GAAP results, determined in accordance with our internal policies, exclude the impact of the following GAAP items (see reconciliation tables below for additional information): share-based compensation expense, fair value adjustment of inventory acquired, amortization of purchased intangible assets, changes in fair value of contingent consideration, restructuring and related expenses, upfront payments related to licenses and other strategic agreements, acquired in-process research and development, impairment of purchased intangible assets, gains and losses related to strategic equity investments, litigation charges, gain or loss on sale of a business or asset, gain or loss related to purchase options, contingent milestone payments associated with acquisitions of legal entities accounted for as asset acquisitions, acquisition-related costs and certain adjustments to income tax expense. … Q4 … The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. For Media enquiries, Megan Goulart, +18573388634, and for Investor Relations, Chris Stevo, +18573389309. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Acquisition-related costs primarily consist of transaction costs, costs associated with the accelerated vesting of equity awards previously granted to employees and employee separation costs. Non-GAAP diluted EPS for the third quarter of 2020 was $3.24, a 16 percent increase versus the third quarter of 2019. Kevin O'Neil Associate Director, Investor Relations at Alexion Pharmaceuticals, Inc. Prior to joining Alexion, Morgan served as a Vice President in Equity Research at Barclays plc with focused coverage on the Specialty Pharmaceuticals and Emerging Biosimilars sector. For the three and nine months ended September 30, 2020, we recorded $63.0 million and $105.7 million, respectively, of acquisition-related costs in connection with the Achillion Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. acquisitions. Corporate Governance. BOSTON--(BUSINESS WIRE)--Oct. 29, 2020-- Alexion Contacts: Media Megan Goulart, 857-338-8634 Executive Director, Corporate Communications Investors Chris Stevo, 857-338-9309 Head of Investor Relations Source: Alexion Pharmaceuticals, Inc. Minimum 15 minutes delayed. A replay of the call will be available for a limited period following the call. Full guidance updates are outlined below. Maintaining a strong balance sheet to fund future exploration and appraisal Adjustments to reconcile net income to net cash flows from operating activities: Unrealized gain on strategic equity investments, Gain on derecognition of Portola strategic equity investment. Executive Director, Corporate Communications, Investors On a GAAP basis, diluted EPS in the quarter was $2.62, compared to $2.08 in the prior year. Total revenues in the third quarter were $1,588.7 million, a 26 percent increase compared to the same period in 2019. (in millions, except per share amounts and percentages) Brenda Eustace. Investors. © 2021 Alexion Pharmaceuticals, Inc. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. The transaction includes the potential for additional consideration in the form of non-tradeable contingent value rights, or CVRs, which will pay our shareholders up to $2.00 per share if certain clinical and regulatory milestones are achieved within specified periods. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those forward-looking statements, including for example: our dependence on sales from our principal product (SOLIRIS); our ability to facilitate the timely conversion from SOLIRIS to ULTOMIRIS; payer, physician and patient acceptance of ULTOMIRIS as an alternative to SOLIRIS; the impact of the COVID-19 pandemic on Alexion’s business, including its sales, clinical trials, operations and supply chain; appropriate pricing for ULTOMIRIS; future competition from biosimilars and novel products; decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or failure of product candidates to obtain regulatory approval; delays or the inability to launch product candidates due to regulatory restrictions, anticipated expense or other matters; interruptions or failures in the manufacture and supply of our products and our product candidates; failure to satisfactorily address matters raised by the FDA and other regulatory agencies; results in early stage clinical trials may not be indicative of full results or results from later stage or larger clinical trials (or broader patient populations) and do not ensure regulatory approval; the possibility that results of clinical trials are not predictive of safety and efficacy and potency of our products (or we fail to adequately operate or manage our clinical trials) which could cause us to halt trials, delay or prevent us from making regulatory approval filings or result in denial of approval of our product candidates; unexpected delays in clinical trials; unexpected concerns that may arise from additional data or analysis obtained during clinical trials; future product improvements may not be realized due to expense or feasibility or other factors; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; inability to complete planned acquisitions due to failure of regulatory approval or material changes in target or otherwise; inability to complete acquisitions and investments due to increased competition for technology; the possibility that current rates of adoption of our products are not sustained; the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us (including intellectual property lawsuits relating to ULTOMIRIS brought by third parties against Alexion and inter partes review petitions submitted by third parties); the risk that third party payors (including governmental agencies) will not reimburse or continue to reimburse for the use of our products at acceptable rates or at all; failure to realize the benefits and potential of investments, collaborations, licenses and acquisitions, including the acquisition of Portola Pharmaceuticals, Inc.; the possibility that expected tax benefits will not be realized or that potential tax liabilities exceed current expectations; assessment of impact of recent accounting pronouncements; potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; uncertainties surrounding legal proceedings, company investigations and government investigations; the risk that estimates regarding the number of patients with PNH, aHUS, gMG, NMOSD, HPP and LAL-D and other indications we are pursuing are inaccurate; the risks of changing foreign exchange rates; risks relating to the potential effects of the Company's restructuring; risks related to the acquisition of companies and co-development and collaboration efforts; and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended June 30, 2020 and in our other filings with the SEC. Investor Relations (Global) Investor Relations (Sweden) Resources Governance Shareholder information Dividend policy Key facts FAQs Debt Investors ADR Programme Media. Updated 2020 financial guidance assumes a GAAP effective tax rate of (5.0) to (4.5) percent and a non-GAAP effective tax rate of 15.5 to 16.0 percent. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. ALEXION PHARMACEUTICALS, INC.TABLE 3: RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL GUIDANCE Reminder: Invitation to the Roche Diagnostics Investor Day 2021: Innovating diagnostics, shaping healthcare, changing lives more Communication regarding transfer requirements, lost certificates and changes of … Alexion's non-GAAP income tax expense for the three and nine months ended September 30, 2020 and 2019 excludes the tax effect of pre-tax adjustments to GAAP profit. This website is intended only for residents of the United States. The Investor Relations website contains information about Transocean Ltd.'s business for stockholders, potential investors, and financial analysts. John Orloff-- Global Head of R&D The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Ludwig Hantson-- Chief Executive Officer. Investor Relations Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives. Greater Boston Area 500+ connections During the nine months ended September 30, 2019, we recorded expense of $76.3 million in connection with upfront payments on strategic agreements that we entered into with Eidos, Affibody AB and Zealand Pharma A/S. Alexion also uses these non-GAAP financial measures to establish budgets, set operational goals and to evaluate the performance of the business. We remain focused on continuing to serve patients, protecting the health and safety of our employees and the communities in which we live and work, and supporting patients in clinical trials. Investor Relations – Allegion. This website is intended only for residents of the United States. Receive FREE instant access to constantly updated ALXN news related to the current merger. In the third quarter, we further progressed our LEAD-EXPAND-DIVERSIFY strategy with multiple regulatory approvals, the initiation of new Phase 3 trials and the integration of the Portola team," said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. NASDAQ: ALXN $152.75 -0.9 (-0.59%) Data Provided by Refinitiv. Aradhana Sarin-- Chief Financial Officer. Alexion is increasing full year 2020 financial guidance. TABLE 1: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS, Cost of sales (exclusive of amortization of purchased intangible assets), Acquired in-process research and development, Change in fair value of contingent consideration, Amortization of purchased intangible assets, Shares used in computing earnings per common share, TABLE 2: RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS, Fair value adjustment in inventory acquired (1), Upfront payments related to licenses and other strategic agreements (2). Alexion does not contact candidates via instant messaging or chat tools. For Media contacts, click here. During the three and nine months ended September 30, 2020, we recorded $11.8 million and $0.7 million within cost of sales and research and development expense, respectively, related to the amortization of the excess fair value of ANDEXXA inventory over the estimated historical cost basis of the inventory, recognized in connection with the acquisition of Portola Pharmaceuticals, Inc. During the three months ended September 30, 2019, we recorded expense of $30.1 million in connection with an upfront payment on a strategic agreement that we entered into with Eidos Therapeutics, Inc. (Eidos). Alexion, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.44 billion for the quarter ended June 2020, … Profile. Alexion Q4 and Full Year 2020 Results. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Filing of certain prospectuses and communications in connection with … Director, Investor Relations +1(617)-341-6187 Main Info Investorinfo@VRTX.com +1(617)-961-7163.
Walsall Mosque Prayer Timetable, Elisabeth Thomas Yale, Katholische Kirche Mitglieder Weltweit, Dimension Terrain De Basket Ffbb, Angeln Main Eltmann, Toy Keyboard Demo,
Neue Kommentare